Completed NA INTERVENTIONAL 2-arm NCT03945708

Does Whole Blood Adsorber During CPB Reduce Vasoactive Drugs Postoperatively in Endocarditis Patients Undergoing Valve Surgery?

Does Whole Blood Adsorber During CPB Reduce the Amount of Vasoactive Drugs Postoperatively in Endocarditis Patients Undergoing Valve Surgery? -a Randomized Controlled Study

Sponsor: CytoSorbents, Inc

Conditions Infective Endocarditis

Interventions CytoSorb

Updated 8 times since 2019 Last updated: Sep 20, 2021 Started: May 15, 2019 Primary completion: Dec 31, 2020 Completion: Dec 31, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Infective Endocarditis and is currently completed. CytoSorbents, Inc leads this study, which shows 8 recorded versions since 2019 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Mar 2025 — Present [monthly]

Completed NA
Feb 2025 — Mar 2025 [monthly]

Completed NA
Sep 2024 — Feb 2025 [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Oct 2021 — Jul 2024 [monthly]

Completed NA

Status: Recruiting → Completed

▶ Show 3 earlier versions

Jan 2021 — Oct 2021 [monthly]

Recruiting NA
Nov 2019 — Jan 2021 [monthly]

Recruiting NA

Phase: PHASE4 → NA
Jun 2019 — Nov 2019 [monthly]

Recruiting PHASE4

First recorded

May 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CytoSorbents, Inc
Emma Hansson

Data source: Sahlgrenska University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Gothenburg, Sweden